NEW DELHI, June 28:
Drug major Dr Reddy’s Laboratories on Monday announced the commercial launch of COVID-19 treatment drug, 2-deoxy-D-glucose (2-DG), at a maximum retail price of Rs 990 per sachet.
The company will supply the drug to major government as well as private hospitals across India, Dr Reddy’s said in a regulatory filing. “In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand THE coverage to the rest of India,” it added.
The drug manufactured by the company has a purity of 99.5 per cent and is being sold commercially under the brand name 2DG. The maximum retail price (MRP) of each sachet has been fixed at Rs 990, with a subsidised rate offered to government institutions, Dr Reddy’s said. “2-DG is yet another addition to our COVID-19 portfolio that already covers the full spectrum of mild to moderate and severe conditions and includes a vaccine. We are extremely pleased to have partnered with DRDO in our collective fight against the COVID-19 pandemic,” Dr Reddy’s Chairman Satish Reddy said.
The drug can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care, Dr Reddy’s said.
Emergency use approval for the anti-COVID-19 therapeutic application of the drug was granted on May 1, 2021, it added.
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s. The filing said.
(PTI)
Follow our WhatsApp channel
